厄洛替尼联合放射治疗食管癌的Meta分析
|
摘要
目的系统评价厄洛替尼联合放疗与单纯放疗治疗食管癌的总有效率及皮疹、消化系统反应发生率。方法检索知网、万方、维普中文科技期刊数据库等有关厄洛替尼联合放疗治疗食管癌的随机对照试验(RCT),搜索截止至2017年4月。按照纳入及排除标准筛选文献,使用RevMan 5.3软件对数据进行统计学评价。结果共纳入6篇RCT,631例食管癌患者。统计结果表明观察组治疗总有效率显著高于对照组,皮疹发生率和消化系统反应发生率显著低于对照组,差异均有统计学意义。结论厄洛替尼联合放疗较单纯放疗提高了治疗总有效率,而皮疹及消化系统反应均有所降低。
Objective To systematically evaluate erlotinib combined with radiotherapy compared with radiotherapy alone in the treatment of,the total incidence rate of esophageal carcinoma reaction efficiency rate of rash and digestive system. Method A randomized controlled trial of erlotinib retrieval CNKI,Wanfang,VIP Chinese science and technology periodical database imatinib combined with radiotherapy for esophageal cancer(RCT)was done,and the deadline was April,2017. The literature was screened according to inclusion and exclusion criteria,and the data were statistically evaluated through using RevMan 5.3 software. Results A total of6 RCT and 631 patients with esophageal cancer were enrolled. The statistical results showed that the total effective rate of the observation group was significantly higher than that of the control group,and the incidence of skin rash and digestive system reaction was significantly lower than the control group. The difference was statistically significant. Conclusion Erlotinib combined with radiotherapy compared with radiotherapy alone improves the treatment efficiency,and the reaction was rash and digestive system decreased.
Objective To systematically evaluate erlotinib combined with radiotherapy compared with radiotherapy alone in the treatment of,the total incidence rate of esophageal carcinoma reaction efficiency rate of rash and digestive system. Method A randomized controlled trial of erlotinib retrieval CNKI,Wanfang,VIP Chinese science and technology periodical database imatinib combined with radiotherapy for esophageal cancer(RCT)was done,and the deadline was April,2017. The literature was screened according to inclusion and exclusion criteria,and the data were statistically evaluated through using RevMan 5.3 software. Results A total of6 RCT and 631 patients with esophageal cancer were enrolled. The statistical results showed that the total effective rate of the observation group was significantly higher than that of the control group,and the incidence of skin rash and digestive system reaction was significantly lower than the control group. The difference was statistically significant. Conclusion Erlotinib combined with radiotherapy compared with radiotherapy alone improves the treatment efficiency,and the reaction was rash and digestive system decreased.
引文
[1]赫捷,陈万青. 2012中国肿瘤登记年报[M].北京:军事医学科学出版社,2012.
[2] YAMASHITA H,OKUMA K,WAKUI R,et al. Detail of recurrence sites afterelective nodal irradiatioin(ENI)using 3Dconformal radiotherpapy(3DCRT)combined with chemotherapy for thoracic esophageal squamouscell carcinoma-a retrospective analysis[J]. Radioth Oncol,2011,98(2):255-260.
[3] ZHAO L,HE L,XI M,et al.Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3[J]. J Transl Med,2012,10(2):249-250.
[4]陈晓亮,王红旗,朱旭勇.放疗联合靶向药物治疗食管癌疗效观察[J].中国实用医药,2016,11(25):156-157.
[5]赵海妮.厄洛替尼联合放疗治疗食管癌的效果观察[J].养生保健指南,2016(22):232.
[6]任萍. EGFR靶向药物治疗食管癌的临床研究[J].中国实用医药,2016,11(5):156-157.
[7]周宓,孙婷婷,杨金霞,等.调强放疗联合厄洛替尼治疗晚期食管癌的疗效观察[J].现代医学,2015,43(4):438-441.
[8]张鹏.放疗联合靶向药物治疗食管癌患者的疗效[J].中国实用医药,2014,9(33):115-116.
[9] PFREIMERM, VATTER P, LANGERT, et al. LARG links histamine-H1-receptor-activated Gq to Rho-GTPase-dependent signaling pathways[J]. Cellular Signalling,2012,24(3):652-663.
[10]原强,兰胜民,郭汝元,等.厄洛替尼与X射线对人食管癌KYSE450细胞生长抑制的影响[J].中华肿瘤防治杂志,2016,23(6):352-353.
[11]高巍,郭俊俊.食管癌外周血及肿瘤组织的EGFR突变的检测及意义[J].癌症进展,2016,14(7):635-636.
[12]张薛榜,谢聪颖,李文峰,等.厄洛替尼联合放疗治疗老年食管癌的Ⅱ期临床观察[J].中华医学杂志,2012,92(23):1615-1617.
[13]李永青.分析放疗联合靶向药物治疗食管癌患者的疗效[J].世界最新医学信息文摘,2014,14(28):38-39.
[14]张军,张钰佳,王亚萍,等.放疗联合靶向药物治疗食管癌患者的疗效[J].中国老年学杂志,2013,33(23):5821-5822.
[15]晋亚楠,夏爱军,梁园.厄洛替尼致不良反应的文献分析[J].中国当代医药,2014,21(24):193-194.
[16]李翔,黄欣欣,周亮,等.厄洛替尼的临床不良反应与治疗对策[J].实用药物与临床,2013,16(2):137-139.
[17]张楠.厄洛替尼不良反应的发生规律及特点分析[J].中国继续医学教育,2016,8(6):141-142.
[2] YAMASHITA H,OKUMA K,WAKUI R,et al. Detail of recurrence sites afterelective nodal irradiatioin(ENI)using 3Dconformal radiotherpapy(3DCRT)combined with chemotherapy for thoracic esophageal squamouscell carcinoma-a retrospective analysis[J]. Radioth Oncol,2011,98(2):255-260.
[3] ZHAO L,HE L,XI M,et al.Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3[J]. J Transl Med,2012,10(2):249-250.
[4]陈晓亮,王红旗,朱旭勇.放疗联合靶向药物治疗食管癌疗效观察[J].中国实用医药,2016,11(25):156-157.
[5]赵海妮.厄洛替尼联合放疗治疗食管癌的效果观察[J].养生保健指南,2016(22):232.
[6]任萍. EGFR靶向药物治疗食管癌的临床研究[J].中国实用医药,2016,11(5):156-157.
[7]周宓,孙婷婷,杨金霞,等.调强放疗联合厄洛替尼治疗晚期食管癌的疗效观察[J].现代医学,2015,43(4):438-441.
[8]张鹏.放疗联合靶向药物治疗食管癌患者的疗效[J].中国实用医药,2014,9(33):115-116.
[9] PFREIMERM, VATTER P, LANGERT, et al. LARG links histamine-H1-receptor-activated Gq to Rho-GTPase-dependent signaling pathways[J]. Cellular Signalling,2012,24(3):652-663.
[10]原强,兰胜民,郭汝元,等.厄洛替尼与X射线对人食管癌KYSE450细胞生长抑制的影响[J].中华肿瘤防治杂志,2016,23(6):352-353.
[11]高巍,郭俊俊.食管癌外周血及肿瘤组织的EGFR突变的检测及意义[J].癌症进展,2016,14(7):635-636.
[12]张薛榜,谢聪颖,李文峰,等.厄洛替尼联合放疗治疗老年食管癌的Ⅱ期临床观察[J].中华医学杂志,2012,92(23):1615-1617.
[13]李永青.分析放疗联合靶向药物治疗食管癌患者的疗效[J].世界最新医学信息文摘,2014,14(28):38-39.
[14]张军,张钰佳,王亚萍,等.放疗联合靶向药物治疗食管癌患者的疗效[J].中国老年学杂志,2013,33(23):5821-5822.
[15]晋亚楠,夏爱军,梁园.厄洛替尼致不良反应的文献分析[J].中国当代医药,2014,21(24):193-194.
[16]李翔,黄欣欣,周亮,等.厄洛替尼的临床不良反应与治疗对策[J].实用药物与临床,2013,16(2):137-139.
[17]张楠.厄洛替尼不良反应的发生规律及特点分析[J].中国继续医学教育,2016,8(6):141-142.